Over a period of seven months, an interventional study involving 94 cases was carried out in a tertiary care center to know the therapeutic outcomes and efficacy of the MMR vaccine in viral warts. At three-week intervals, a volume of 0.3 ml of MMR vaccine was reconstituted with sterile water and injected into the largest wart until complete remission, or for a maximum of three treatments. Patients were examined after a six-month observation period to look for recurrence, and the degree of response was classified as total, partial, or none at all. Prior approval from the Ethics committee was taken. A total of 100 patients with veruca vulgaris (common warts) attending the outpatient department (OPD) of dermatology and giving written consent were enrolled, out of which six cases were lost to follow-up. Hence 94 cases were studied.
Inclusion criteria
Healthy male and female (without childbearing potential) aged 10 to 45 years with a clinical diagnosis of verruca vulgaris, no concurrent systemic, or topical treatment of warts within the past two weeks attending the dermatology OPD, and cases with multiple common warts. Multiple warts were defined as more than five common warts at a single anatomic site or one or more common warts at more than one anatomical site.
Exclusion criteria and methods
Cases with fever or signs of any inflammation or infection, systemic and/or cutaneous diseases, asthma or allergic skin conditions, meningitis, or convulsions in the past, history of any live vaccine or immunoprophylactic drug within the last three months, and immunocompromised cases were excluded from the study. After informed consent, detailed history was taken followed by a proper cutaneous examination.
MMR vaccine was reconstituted with sterile water and a volume of 0.3 ml was injected with an insulin syringe into the base of the largest wart. This was repeated every three weeks until complete clearance of all warts or for a maximum of three treatments. The response was graded as complete, partial, or no response and was followed up after a period of six months to detect recurrence if any.
Friedman test was used to analyze the relationships between variables. A mean rank table was established to assess the final outcome of the study.
Inclusion criteria
Healthy male and female (without childbearing potential) aged 10 to 45 years with a clinical diagnosis of verruca vulgaris, no concurrent systemic, or topical treatment of warts within the past two weeks attending the dermatology OPD, and cases with multiple common warts. Multiple warts were defined as more than five common warts at a single anatomic site or one or more common warts at more than one anatomical site.
Exclusion criteria and methods
Cases with fever or signs of any inflammation or infection, systemic and/or cutaneous diseases, asthma or allergic skin conditions, meningitis, or convulsions in the past, history of any live vaccine or immunoprophylactic drug within the last three months, and immunocompromised cases were excluded from the study. After informed consent, detailed history was taken followed by a proper cutaneous examination.
MMR vaccine was reconstituted with sterile water and a volume of 0.3 ml was injected with an insulin syringe into the base of the largest wart. This was repeated every three weeks until complete clearance of all warts or for a maximum of three treatments. The response was graded as complete, partial, or no response and was followed up after a period of six months to detect recurrence if any.
Friedman test was used to analyze the relationships between variables. A mean rank table was established to assess the final outcome of the study.
Free full text: Click here
